Enliven Therapeutics, Inc. (ELVN): director Kristine Ball elected to the board

Events in this filing

Item 5.02 as filed

Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Director
On October 14, 2026, the board of directors (the “Board”) of Enliven Therapeutics, Inc. (the “Company”) increased the size of the Board from seven to eight directors and appointed Kristine Ball to serve as a Class II director, with a term expiring at the Company’s 2028 annual meeting of stockholders, and as a member of the Audit Committee of the Board (the “Audit Committee”), effective October 14, 2026.
There are no transactions in which Ms. Ball has an interest that would require disclosure under Item 404(a) of Regulation S-K.
Ms. Ball will receive compensation for her service pursuant to the Company’s Outside Director Compensation Policy. This includes annual cash compensation of: (i) $45,000 per year for service as an outside director; and (ii) $10,000 per year for service as a member of the Audit Committee.
Additionally, as a new outside director, Ms. Ball was granted stock options to purchase shares of the Company’s common stock with a grant date fair value as determined in accordance with U.S. generally accepted accounting principles equal to approximately $650,000. These stock options will vest as to 1/36th of the total number of shares on each monthly anniversary of the grant date, subject to Ms. Ball’s continued service through the applicable vesting date. In the event of a Change in Control (as defined in the Company’s Outside Director Compensation Policy), the stock options will vest in full. In addition, the Company entered into its standard form of indemnification agreement with Ms. Ball. There are no arrangements or understandings between Ms. Ball and any other person pursuant to which she was selected as a director.